Role of interferon for the treatment of myeloma

Shuhei Tomita, Shinichiro Okamoto

Research output: Contribution to journalArticle

Abstract

Interferon (IFN)-alpha inhibits the growth of myeloma cell lines by inducing apoptosis. Based upon this finding, IFN has been evaluated in clinical trials as single-agent induction therapy, induction in combination with chemotherapy, and as maintenance therapy in plateau phase. Available data suggest that progression-free survival is improved with IFN, but the survival benefit is small. IFN has also been evaluated as maintenance after high-dose chemotherapy; however, the true benefit of IFN maintenance remains to be elucidated in view of conflicting data. In an area of rapidly increasing treatment options, novel agents, which have less toxicity and more biologic rationale, outweigh the limited benefits for IFN.

Original languageEnglish
Pages (from-to)2285-2290
Number of pages6
JournalNippon rinsho. Japanese journal of clinical medicine
Volume65
Issue number12
Publication statusPublished - 2007 Dec

Fingerprint

Interferons
Maintenance
Therapeutics
Combination Drug Therapy
Interferon-alpha
Disease-Free Survival
Clinical Trials
Apoptosis
Drug Therapy
Cell Line
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Role of interferon for the treatment of myeloma. / Tomita, Shuhei; Okamoto, Shinichiro.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 65, No. 12, 12.2007, p. 2285-2290.

Research output: Contribution to journalArticle

@article{a9b82f615b634a85a91ab6380fd1d3c3,
title = "Role of interferon for the treatment of myeloma",
abstract = "Interferon (IFN)-alpha inhibits the growth of myeloma cell lines by inducing apoptosis. Based upon this finding, IFN has been evaluated in clinical trials as single-agent induction therapy, induction in combination with chemotherapy, and as maintenance therapy in plateau phase. Available data suggest that progression-free survival is improved with IFN, but the survival benefit is small. IFN has also been evaluated as maintenance after high-dose chemotherapy; however, the true benefit of IFN maintenance remains to be elucidated in view of conflicting data. In an area of rapidly increasing treatment options, novel agents, which have less toxicity and more biologic rationale, outweigh the limited benefits for IFN.",
author = "Shuhei Tomita and Shinichiro Okamoto",
year = "2007",
month = "12",
language = "English",
volume = "65",
pages = "2285--2290",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "12",

}

TY - JOUR

T1 - Role of interferon for the treatment of myeloma

AU - Tomita, Shuhei

AU - Okamoto, Shinichiro

PY - 2007/12

Y1 - 2007/12

N2 - Interferon (IFN)-alpha inhibits the growth of myeloma cell lines by inducing apoptosis. Based upon this finding, IFN has been evaluated in clinical trials as single-agent induction therapy, induction in combination with chemotherapy, and as maintenance therapy in plateau phase. Available data suggest that progression-free survival is improved with IFN, but the survival benefit is small. IFN has also been evaluated as maintenance after high-dose chemotherapy; however, the true benefit of IFN maintenance remains to be elucidated in view of conflicting data. In an area of rapidly increasing treatment options, novel agents, which have less toxicity and more biologic rationale, outweigh the limited benefits for IFN.

AB - Interferon (IFN)-alpha inhibits the growth of myeloma cell lines by inducing apoptosis. Based upon this finding, IFN has been evaluated in clinical trials as single-agent induction therapy, induction in combination with chemotherapy, and as maintenance therapy in plateau phase. Available data suggest that progression-free survival is improved with IFN, but the survival benefit is small. IFN has also been evaluated as maintenance after high-dose chemotherapy; however, the true benefit of IFN maintenance remains to be elucidated in view of conflicting data. In an area of rapidly increasing treatment options, novel agents, which have less toxicity and more biologic rationale, outweigh the limited benefits for IFN.

UR - http://www.scopus.com/inward/record.url?scp=39549091370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39549091370&partnerID=8YFLogxK

M3 - Article

C2 - 18069274

AN - SCOPUS:39549091370

VL - 65

SP - 2285

EP - 2290

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 12

ER -